Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multi-arm study of quavonlimab/pembrolizumab and other pembrolizumab-based combinations versus pembrolizumab in MSI-H/dMMR stage IV colorectal cancer
NL-OMON53742Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of quavonlimab, pembrolizumab, favezelimab, vibostolimab and mk-4830 in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Merck & Co. Primary endpoint: Objective response rate by blinded independent central review. Started Apr 2023; status: recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON53742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53742.